Three Bottles, One Molecule: Dextromethorphan on the Cough Shelf and in the Cabinet
Dextromethorphan is a cough suppressant, a prescription antidepressant, and an over-the-counter medicine teenagers misuse. How the three bottles differ.

Most households with a cough medicine in them own the same molecule twice and do not know it. There is a bottle of single-ingredient cough syrup, the one that says dextromethorphan and nothing else on the active-ingredients panel. There is a "nighttime" bottle where dextromethorphan is one of three or four active ingredients. And increasingly there is a prescription tablet, in a household with an adult being treated for depression, that contains dextromethorphan as well.
All three are the same drug. None of them behave the same way.
That matters because dextromethorphan sits at an unusual intersection. At the doses printed on a cough label it is a modest suppressant with a good safety record. Above roughly 2 mg per kilogram of body weight it stops being a cough medicine and starts producing dissociation, hallucinations and, in some people, seizures. It is also the over-the-counter medicine most consistently associated with adolescent misuse, and since the 2020s an FDA-approved antidepressant. The same molecule is sold as a comfort product and prescribed as a psychiatric drug, and the difference is dose, formulation and what else is in the pill.
Here is how to tell the three bottles apart, and what to do when the arithmetic goes wrong.
The same molecule at three different doses
The labels are the place to start, because the numbers are not intuitive.
A single-ingredient cough syrup such as Delsym contains dextromethorphan polistirex equivalent to 30 mg of dextromethorphan hydrobromide in every 5 mL. The adult directions are 10 mL every 12 hours, not to exceed 20 mL in 24 hours. That is 120 mg a day, in two doses, and it is the ceiling the manufacturer puts on the product.
A combination product such as Delsym Nighttime Cough puts 20 mg of dextromethorphan, 650 mg of acetaminophen and an antihistamine in every 20 mL. The directions allow four doses in 24 hours: 80 mL, carrying 80 mg of dextromethorphan and 2,600 mg of acetaminophen.
The prescription product, Auvelity, is a tablet containing 45 mg of dextromethorphan hydrobromide and 105 mg of bupropion hydrochloride. The maximum dose is one tablet twice daily, at least eight hours apart, for a total of 90 mg of dextromethorphan a day.
Read those three numbers together. The prescription delivers less dextromethorphan in a day than the cough syrup label permits, and it is by far the most potent of the three. Families assume the bottle with the biggest number on the front is the strong one. It is not. Potency here is set by what the body does with the drug, not by how much of it is in the container.
What dextromethorphan does when the dose rises
Dextromethorphan is an uncompetitive antagonist of the NMDA receptor, the same glutamate receptor that ketamine blocks, and an agonist at the sigma-1 receptor. The FDA label for the prescription product describes exactly that mechanism. The cough effect comes from activity in the brainstem; the dissociative effect at higher doses comes from the same NMDA blockade that makes ketamine a dissociative anesthetic.
A clinical review published in the Journal of the American Pharmacists Association puts the threshold at roughly 2 mg per kilogram. Above that dose the drug produces a dissociative state that users describe in terms borrowed from ketamine and PCP. Converted into a body a parent can picture: for a 110-pound teenager, 2 mg/kg is about 100 mg, which is under the 120 mg the cough label allows in a single day. For a 130-pound teenager it is about 120 mg, which is exactly the daily maximum on the bottle.
Nothing on the bottle is wrong. The label is written for a person with a cough taking two measured doses twelve hours apart, not for a person taking the day's supply at once, and the two are far closer together than the packaging suggests.
CYP2D6 is a switch, not a volume knob
Most of a dextromethorphan dose is broken down by an enzyme called CYP2D6 into dextrorphan. The two molecules do not do the same thing. Dextrorphan is the more potent blocker of the NMDA channel; the parent drug, dextromethorphan, is the more potent inhibitor of the serotonin transporter.
A 2026 pharmacology review in the International Journal of Molecular Sciences makes the consequence explicit: CYP2D6 activity does not simply scale how much drug effect you get, it determines which pharmacology is expressed. When the enzyme is inhibited, the parent compound accumulates, and the model in that review calculates that CYP2D6 inhibition raises the serotonergic component roughly fourfold while reducing the NMDA channel component.
This is not an abstraction. It is the design principle behind the prescription tablet. Bupropion is a CYP2D6 inhibitor, and the label states plainly that it increases plasma levels of dextromethorphan by competitively inhibiting the enzyme. The label's pharmacokinetic section quantifies it: at steady state, dextromethorphan given with bupropion accumulates 20-fold by peak concentration and 32-fold by total exposure, against 1.3-fold and 1.4-fold when it is given alone. The elimination half-life stretches to about 22 hours, roughly a threefold increase.
So the prescription is not "cough syrup in a pill." It is a different drug exposure, engineered on purpose, and it behaves like one.
The combination bottle: the acetaminophen runs out first
Here is the arithmetic that almost nobody does, and it is the most practically useful part of this guide.
The 180 mL bottle of a dextromethorphan-and-acetaminophen nighttime syrup holds nine doses of 20 mL. Nine doses carry 5,850 mg of acetaminophen and 180 mg of dextromethorphan. The label permits four of those doses a day, which is 2,600 mg of acetaminophen. A single bottle therefore holds more than twice the acetaminophen the product's own label allows in 24 hours.
Now apply the overdose thresholds. To reach 7.5 mg/kg of dextromethorphan in a 60 kg person — the dose at which a consensus guideline says to send the patient to an emergency department — you would need 450 mg of dextromethorphan. From this product that is 22.5 doses, or 450 mL, or two and a half bottles. The acetaminophen that comes with it would be 14,625 mg.
This is the point families miss when they hear "cough medicine overdose." In a combination product the dextromethorphan is not the ingredient that runs out first. The acetaminophen does, and the injury that follows a large ingestion is first a liver injury. The label warns about it in a boxed "liver warning" that names the mechanism: severe liver damage may occur if you take more than the maximum daily amount, with other drugs containing acetaminophen, or with three or more alcoholic drinks a day.
The practical rule: read the active-ingredients panel before you read the front of the box. If the panel says acetaminophen, the product cannot be pushed. It cannot become a high-dose dextromethorphan product without a toxic dose of a second drug. The single-ingredient syrups and gelcaps are the ones that can.
The prescription: what dextromethorphan-bupropion is, and is not
The prescription tablet is approved for major depressive disorder in adults. The current label, revised in August 2026, shows a second indication added in April 2026 for agitation associated with dementia due to Alzheimer's disease, with a slower titration that starts at 30 mg of dextromethorphan.
Neither component is a controlled substance, so the product arrives without the restrictions that apply to stimulants or benzodiazepines. It carries a boxed warning about suicidal thoughts and behaviors in pediatric and young adult patients, and it is not approved for use in pediatric patients at all.
A 2023 systematic review of the trials reported depression scores separating from placebo by week one, with a mean 2.2-point MADRS difference, and a 4.7-point difference against an active comparator at two weeks. It is a real antidepressant, in other words, not a marketing repackaging of a cough medicine.
It is contraindicated in anyone taking a monoamine oxidase inhibitor, or within 14 days of stopping one, because of the risk of hypertensive crisis and serotonin syndrome. The label also warns that combining it with an SSRI or a tricyclic antidepressant raises serotonin syndrome risk.
The most common adverse reaction in the depression trial was dizziness, at 16 percent against 6 percent on placebo. The label warns about it directly because of falls. Bupropion can also produce a false-positive amphetamine result on a routine urine immunoassay, which matters for anyone in a monitoring program.
The label also contains a sentence that most people who take this medicine have never read: "Cases of dextromethorphan abuse have been reported, predominantly in adolescents." The manufacturer is required to write that, and it is the bridge between the prescription in the cabinet and the bottle on the shelf.
Which produces the single household rule that follows from all of this. If someone in the house is taking dextromethorphan-bupropion, no over-the-counter cough product containing dextromethorphan should come into that house without a pharmacist checking it. The prescription label instructs prescribers to screen patients for other medicines containing bupropion or dextromethorphan before starting. The patient and the family are the second line of that screen, and the only one that operates on a Saturday night.
What the poison-center data actually shows
The epidemiology is unusually good: FDA's own scientists have published analyses of the National Poison Data System, which collects near-real-time poison-center call data.
The foundational paper, published in Clinical Toxicology in 2018, covered 2000 through 2015. Single-substance dextromethorphan intentional-abuse call rates tripled between 2000 and 2006, then plateaued. Adolescents aged 14 to 17 carried the highest burden: a mean of 1,761 calls a year, 103.6 per million population. Between 2006 and 2015 that rate fell 56.3 percent, to 80.9 per million.
Two 2026 papers by the same group extend the picture through the pandemic. In adults, exposures fell at the onset, then unintentional therapeutic errors rebounded in some subgroups, particularly women, at about three additional cases a month, surpassing pre-pandemic levels by the end of the public health emergency.
The pediatric paper is the one that should change how families talk about this. Across the cold and cough drugs studied, 88 to 93 percent of intentional pediatric cases involved adolescents aged 13 to 17, and 56 to 71 percent involved females. And the reason for the ingestion was not what the popular story predicts: depending on the drug, 55 to 78 percent of cases were coded as intentional suspected suicide, against 17 to 40 percent coded as intentional abuse or misuse. Dextromethorphan-specific suspected-suicide rates among adolescents fell at the pandemic's onset rather than rising, which is worth stating plainly rather than bending into a trend.
The reframe is the useful part. A teenager who takes a large amount of cough medicine is more often in a mental health crisis than experimenting, and a response that treats every ingestion as a drug-seeking stunt misses the one that carries the higher risk.
What an overdose looks like, and when it is an emergency
The prescription label lists the symptoms of dextromethorphan overdose: nausea and vomiting, stupor, coma, respiratory depression, seizures, rapid heart rate, hyperexcitability and toxic psychosis, plus ataxia, nystagmus, dystonia and blurred vision. There is no antidote.
A consensus guideline for out-of-hospital management, published in Clinical Toxicology, gives triage thresholds that are worth knowing in advance:
- A person who has ingested 5 to 7.5 mg/kg needs poison-center follow-up about every two hours for up to four hours after ingestion, and referral to an emergency department if more than mild symptoms develop.
- A person who has ingested more than 7.5 mg/kg should go to an emergency department for evaluation.
- A person who is asymptomatic more than four hours after ingestion can be observed at home.
- Do not induce vomiting. Do not give activated charcoal at home.
The four-hour rule has a caveat that matters for the extended-release form. Dextromethorphan polistirex, the formulation in the twelve-hour syrups, releases slowly and lasts roughly two to three times as long as the standard formulation. A published pediatric case describes a 23-month-old who ingested 71.4 mg/kg of the polistirex product and required intubation, with a blood level of 110 ng/mL against a therapeutic range of 10 to 40. With the slow-release product, a four-hour observation window is not the same test it is for the immediate-release drug.
Death from dextromethorphan alone is rare but documented: a 2024 autopsy report describes a man in his early twenties with no other drug detected. Naloxone is not an antidote. The consensus guideline allows that it can be considered in a patient who is sedated or comatose with respiratory depression, and the effect is inconsistent. The rule that keeps people alive is simpler: if there is any chance an opioid is involved, give naloxone, call 911, and say the word dextromethorphan out loud when the paramedics arrive.
Call 911 rather than poison control if the person has a seizure, cannot be woken, is breathing slowly or not at all, has chest pain or a racing heartbeat, or is hallucinating in a way you cannot manage. Call Poison Help at 1-800-222-1222 for everything else, including the question "is this amount a problem?" That line is free, confidential and staffed around the clock, for exactly the four hours in which a family is deciding whether to drive to the hospital.
Serotonin syndrome: the combination that goes wrong quietly
The interaction that produces the most avoidable harm is not overdose. It is an ordinary dose on top of an ordinary prescription.
A case report in BMJ Case Reports describes a 63-year-old woman maintained on escitalopram who was prescribed a dextromethorphan-promethazine cough syrup. Two weeks later she presented lethargic and obtunded, with inducible myoclonus and a prolonged QT interval, and no other cause on toxicology screening. Both drugs were stopped and she recovered.
That is the pattern: agitation or drowsiness, muscle jerks and hyperreflexia, tremor, sweating, fever, diarrhea, and in severe cases rigidity and unstable blood pressure. It does not require an overdose, and it does not always announce itself as an emergency.
The drugs that stack with dextromethorphan include SSRIs and SNRIs, tricyclics, monoamine oxidase inhibitors, tramadol, linezolid and intravenous methylene blue. If anyone in the household takes any of those, the correct move before buying a cough product is to hand the box to a pharmacist and ask whether it is compatible. That takes two minutes and is the highest-value question in this entire guide.
What families notice before anyone calls it a problem
No single signal is proof, but the pattern usually shows up at home first.
- Single-ingredient dextromethorphan products appearing in a teenager's room, backpack or car rather than in the cabinet, or bottles emptying faster than the cough in the house would explain.
- Empty blister packs or gelcap shells, which are the high-dose route.
- Language from the online communities that use it recreationally, including "dex," "robotripping" and numbered plateaus.
- A teenager who is unusually withdrawn or unusually flat after an illness, or who has a cough that never seems to resolve while the medicine keeps being replaced.
The last two deserve emphasis. A persistent "cough" can be a reason to keep buying the product, and a flat mood after a binge can look like ordinary teenage withdrawal. The 2026 pediatric data says the mood is often the actual story.
What helps, and what backfires
What helps:
- Reduce the supply of single-ingredient dextromethorphan in the house to one bottle, counted, and keep it where the rest of the medicines are kept. The storage and disposal guide covers the mechanics.
- Treat the combination products separately, because they are the ones that cause liver injury, and the pediatric ingestion guide covers what to do in the first ten minutes.
- Tell every prescriber and every pharmacist about every over-the-counter cough product in use, especially if the household includes a dextromethorphan-bupropion prescription or an SSRI.
- Keep naloxone in the house anyway, because the counterfeit supply is a separate problem that does not announce itself, and the naloxone guide explains how to get it free.
What backfires:
- The confiscation-and-lecture move, which teaches the person to hide the next bottle better and closes the conversation you need.
- "It's just cough medicine," which is the sentence that keeps a parent from calling poison control during the four hours when the call is most useful.
- Assuming one bottle means one problem. The bottle is the visible part of a mood problem more often than it is the whole problem, and clearing the house of every medicine at once is a separate safety project that does not touch the reason.
Where to get help
- Emergency: 911 for seizure, unresponsiveness, slow or stopped breathing, chest pain, or psychosis you cannot manage.
- Poison Help: 1-800-222-1222, free and 24/7, for any question about an amount, a combination or a child.
- 988 Suicide and Crisis Lifeline: call or text 988 if the ingestion was intentional or you are worried about someone's safety.
- SAMHSA National Helpline: 1-800-662-4357, free and confidential, for treatment referrals.
The bottom line
Dextromethorphan is one molecule sold at three very different potencies: a cough syrup capped at 120 mg a day, a combination product whose real limiting ingredient is acetaminophen, and a prescription antidepressant that multiplies the drug's exposure twenty-fold or more by blocking the enzyme that clears it. The dose that produces dissociation in an ordinary teenager is roughly the dose the cough label allows in a day. And the most common reason an adolescent ends up in a poison-center record for it is not curiosity.
None of that makes the medicine dangerous in the way the word usually means. It makes it a drug whose risk lives in the gap between a teaspoon and a bottle.
Sources
- FDA prescribing information — AUVELITY (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets, label version 2026-08-17
- DailyMed — Delsym (dextromethorphan polistirex) over-the-counter Drug Facts label, 2026
- DailyMed — Delsym Nighttime Cough (acetaminophen, dextromethorphan HBr, triprolidine) Drug Facts label, 2026
- Chyka PA et al. — Dextromethorphan poisoning: an evidence-based consensus guideline for out-of-hospital management, Clin Toxicol 2007
- Karami S et al. — Trends in dextromethorphan cough and cold products: 2000-2015 National Poison Data System intentional abuse exposure calls, Clin Toxicol 2018
- Karami S et al. — Adult U.S. poison center exposure case trends involving nonprescription dextromethorphan amid the COVID-19 pandemic, J Med Toxicol 2026
- Karami S et al. — Intentional pediatric nonprescription cold/cough and analgesic/antipyretic exposure trends amid the COVID-19 pandemic, Clin Toxicol 2026
- Romanelli F, Smith KM — Dextromethorphan abuse: clinical effects and management, J Am Pharm Assoc 2009
- Fagiolini A et al. — Dextromethorphan-bupropion-esketamine triadic pharmacology: molecular targets and enzymatic interactions, Int J Mol Sci 2026
- Seltzer JA et al. — Life-threatening pediatric dextromethorphan polistirex overdose, Am J Emerg Med 2022
- Hasuwa K et al. — An autopsy case of a young man with a single overdose of dextromethorphan, Leg Med 2024
- Dy P et al. — Serotonin syndrome caused by drug interaction between escitalopram and dextromethorphan, BMJ Case Rep 2017
- Akbar D et al. — Dextromethorphan-bupropion for the treatment of depression: a systematic review of efficacy and safety, CNS Drugs 2023
- SAMHSA National Helpline
You might also read


